X

Fulford (India) Ltd Stock Analysis

Small Cap
Evaluated by 130 users | BSE: 506803 | NSE: FULFORD |
Trading
Fulford was incorporated in 1948. It was then registered under the name C E Fulford and was 100% owned by C E Fulford Limited of UK. Until 1968, the company was engaged in the business of manufacturing and marketing pharmaceutical consumer products, including cough tablets and herbal...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Dec'10Dec'11Dec'12Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Capital Employed 6.8%3.39%-3.1%3.47%1.64%-9.93%12.28%10.96%15.16%13.46%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 19021421521621715814412399.7109
Y-o-Y Gr. Rt.-12.6%0.6%0.2%0.6%-27.3%-8.8%-14.5%-19%9.7%
Adjusted EPS (Rs.) 24.6612.92-11.819.065.94-36.4345.4245.5271.2472.65
Y-o-Y Gr. Rt.--47.6%-191.4%NA-34.4%-713.3%NA0.2%56.5%2%
Book Value per Share (Rs.) 384.24384.89370.93304.03384.16347.9393.36437.87507.93579.37
Adjusted Net Profit 9.65-4.63.52.3-14.217.717.827.828.3
Net Op. Cash Flow (Rs. Cr.) 611.2-26.67.2-75.65.616.97.56.63.7
Debt to Cash Flow from Ops 0000000000
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Fulford (India) Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales -6%-12.8%-8.8%9.7%
Adjusted EPS 12.8%65%17%2%
Book Value per Share 4.78.613.814.1
Share Price - - - -
Key Financial Parameter
Performance Ratio Colour Code Guide
 Dec'10Dec'11Dec'12Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Equity (%) 6.643.36-3.133.021.55-9.9512.2510.9515.0613.36
Operating Profit Margin (%) 5.03-0.15-6.77-1.72-3.98-17.1515.718.221.1127.5
Net Profit Margin (%) 5.062.35-2.141.641.07-9.0112.3114.4227.8625.91
Debt to Equity 0000000000
Working Capital Days 256244251198281410438410347348
Cash Conversion Cycle 1445-64061-12-103-71-60
Entity Percentage Holding
Promoters 94.57%
Institutions 0.04%
Non-Institutions 5.39%
Others 0.01%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

Data is not available for this company.

Data is not available for this company

Fulford was incorporated in 1948. It was then registered under the name C E Fulford and was 100% owned by C E Fulford Limited of UK. Until 1968, the company was engaged in the business of manufacturing and marketing pharmaceutical consumer products, including cough tablets and herbal ointments, marketed under the trademarks – PEPS and ZAMBUK respectively.

The company offers medicines for the treatment of allergy & respiratory, arthritis & immunology, cancer therapies,

Fulford was incorporated in 1948. It was then registered under the name C E Fulford and was 100% owned by C E Fulford Limited of UK. Until 1968, the company was engaged in the business of manufacturing and marketing pharmaceutical consumer products, including cough tablets and herbal ointments, marketed under the trademarks – PEPS and ZAMBUK respectively.

The company offers medicines for the treatment of allergy & respiratory, arthritis & immunology, cancer therapies, cardiovascular, hepatitis, sun care, etc.

Fulford is a subsidiary of Schering-Plough Corporation, USA, a leading research-based company, engaged primarily in the discovery, development, manufacturing and marketing of pharmaceutical and health care products worldwide.

On July 1, 1968, Schering-Corporation, USA, an international research-based pharmaceutical company acquired 100% ownership of C. E. Fulford Limited, UK. Subsequently, a manufacturing plant was set up at Andheri for the manufacture of pharmaceutical products. The company’s operations commenced with the introduction of an antibiotic injection under the brand name GARAMYCIN and an antifungal skin solution under the brand name TINADERM.

In 1971, Schering Corporation merged with Plough Inc., a mass merchandiser of popular consumer products and Schering-Plough Corporation was formed. Schering-Plough has its headquarters and executive offices at New Jersey, USA.

 In August 1981, the company changed its status from a private company to a public company and from January 1, 1982 diluted the foreign shareholding from 100% to 40%, to fall in line with the prevailing government policy. The shares of Fulford are listed on the Bombay Stock Exchange. There have been three bonus issues in the ratios of 1:1 since the public issue of shares.

It is committed to earning the trust of doctors, patients and customers every day. Their colleagues worldwide believe that trust is not easily granted, and that is the reason they focus each day on becoming a champion for their stakeholders. During the past few years, the company has been building a new kind of health care company. Their scientists are earning trust through the discovery and development of innovative, science-based medicines and services that improve the health and well-being of people around the world.

The test of  being a true champion is to never give up and to passionately strive for even better outcomes. From their perspective as a health care company, that means helping people live better and live longer

Fulford offers medicines in the following areas:

  • Allergy & Respiratory
  • Arthritis & Immunology 
  • Cancer Therapies 
  • Cardiovascular 
  • Hepatitis 
  • Sun Care  
  • Skin Disorders 
  • Systemic Anti Infective 

Key Products of the company include:

Quadriderm RF, Dipsalic F, Elocon, Alaspan, Netromyicin, Remicade, Viraferon Peg, Integrilin etc.

Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback